PMID: 8947584Sep 1, 1996Paper

Heterogenous effects of bryostatin on human myeloid leukemia clonogenicity: dose and time scheduling dependency

Leukemia Research
K G van der HemP C Huijgens

Abstract

The potent anti-neoplastic actions displayed in vitro by bryostatins have led to the introduction of short-term bryostatin-1 infusions in phase I clinical trials. Because bryostatin (bryo) undergoes a rapid clearance in vivo, we were interested in its scheduling effects on acute myeloid leukemia (AML) clonogenicity. Therefore, we assessed the primary plating efficiency (PE1) of AML samples in response to several bryo concentrations after various preincubation periods in a semi-solid colony forming assay. Whereas continuous exposure to 10 nM bryo during the assay period reduced the PE1 in nearly all samples tested, preincubation of eight AML patients' specimens for 1, 2, 3 or 4 days with bryo in a dose range of 0.1-10 nM showed a heterogenous PE1 response. Stimulatory as well as inhibitory effects on leukemic clonogenic growth were seen within individual specimens depending on dose and preincubation time with no single incubation time or concentration that caused unequivocal common overall inhibition of clonogenic growth in most or all of the samples. Higher doses of bryo also failed to result in specific inhibition of leukemic cells: 4/8 samples showed an increased clonogenic response to 250 nM bryo whereas normal bone marrow p...Continue Reading

References

May 8, 1992·Biochemical Pharmacology·N E LewinB S Warren
Nov 17, 1993·Journal of the National Cancer Institute·A S Kraft
Aug 1, 1993·British Journal of Cancer·J PrendivilleM Potter
Jan 1, 1993·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J PrendivilleD Crowther
Jan 1, 1996·Cancer Chemotherapy and Pharmacology·A S KraftF Wagner
Nov 1, 1995·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·D A Joyce, J H Steer

❮ Previous
Next ❯

Citations

Jul 5, 2005·Expert Opinion on Investigational Drugs·H T Zhang, A L Harris
Apr 3, 1999·British Journal of Cancer·S F ThijsenG J Ossenkoppele

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.